Pre-made Ramucirumab benchmark antibody ( Whole mAb, anti-KDR therapeutic antibody, Anti-FLK1/CD309/VEGFR/VEGFR2 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-468
Pre-Made Ramucirumab biosimilar, Whole mAb, Anti-KDR Antibody: Anti-FLK1/CD309/VEGFR/VEGFR2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ramucirumab (LY3009806, IMC-1121B, trade name Cyramza) is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Ramucirumab biosimilar, Whole mAb, Anti-KDR Antibody: Anti-FLK1/CD309/VEGFR/VEGFR2 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||3s34:HL/3s37:HL/3s36:HL|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Dyax;AstraZeneca;Dana-Farber Cancer Institute;Eli Lilly;Merck Sharp & Dohme;University of Texas M. D. Anderson Cancer Center;Washington University School of Medicine|
|Conditions Approved||Colorectal cancer;Gastric cancer;Non-small cell lung cancer;Liver cancer|
|Conditions Active||Oesophageal cancer;Urogenital cancer;Biliary cancer;Carcinoid tumour;Solid tumours;Pancreatic cancer|
|Conditions Discontinued||Breast cancer;Malignant melanoma;Ovarian cancer;Prostate cancer;Renal cell carcinoma|
|Development Tech||Dyax Human Phage Display|